Ixifi, a Biosimilar of Remicade, Receives Approval

The FDA approved infliximab-qbtx (Ixifi, Pfizer), a biosimilar of Janssen’s Remicade brand of infliximab for all eligible indications as the reference product. 

Infliximab-qbtx is a chimeric human–murine monoclonal antibody against tumor necrosis factor, which will be indicated for patients with rheumatoid arthritis (RA), Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.